POINT Biopharma Global — Investor Presentation (February 2022)
47 slides from POINT Biopharma Global's investor presentation, Feb 25, 2022

Slide 1: Accelerating Precision Medicine Investor Presentation
Accelerating Precision MedicineTM 1 February 2022 Investor Presentation NASDAQ: PNT Accelerating Precision Medicine™

Slide 2: Legal Disclaimer
Accelerating Precision MedicineTM Legal Disclaimer 2 Except as otherwise indicated or unless the context otherwise requires, all references in this presentation to “we,” “our,” “us,” “POINT,” or the “Company” refer to POINT Biopharma Global Inc. This information contained in this presentation does n

Slide 3: POINT Biopharma: Creating the platform for next-generation radiopharmaceuticals
Accelerating Precision MedicineTM POINT Biopharma: Creating the platform for next-generation radiopharmaceuticals 3 POINT’S MISSION Accelerating the discovery, development and global access to life-changing radiopharmaceuticals POINT’S VISION Transforming lives touched by cancer INDUSTRY-LEADING PIP

Slide 4: Radiopharmaceuticals will be a new pillar of oncology treatment
Accelerating Precision MedicineTM Radiopharmaceuticals will be a new pillar of oncology treatment with pan-cancer opportunities 4 MOLECULARLY TARGETED RADIATION Radiotherapy is a proven pillar of cancer treatment but lacks precision. By precisely delivering radiation directly to cancer cells with ra

Slide 5: One of the most experienced radiopharmaceutical development and manufacturing teams
Accelerating Precision MedicineTM POINT has assembled one of the most experienced teams in the clinical development and manufacturing of radiopharmaceuticals 5 + 40+ CLINICAL TRIALS 30+ INDS, 30+ CTAS, 10+ INTERNATIONAL TRIALS + 12 APPROVALS 10 NDA/NDSS, 5 ANDA, 1 SNDS, 2 DMFS + 8 GMP RADIOPHARMACEU

Slide 6: Novel ligands are expanding the cancer indications treatable with radiopharmaceuticals
Accelerating Precision MedicineTM Novel ligands are greatly expanding the number of cancer indications that can be treated with radiopharmaceuticals 1. Baum et al. J Nucl Med 2016 6 Radioligands enable the precise targeting of cancer by combining a radioisotope, a linker & a targeting moiety that se

Slide 7: New radioisotopes are further enhancing radiopharmaceuticals' capabilities
Accelerating Precision MedicineTM New radioisotopes are further enhancing radiopharmaceuticals’ capabilities 7 POINT leverages the unique properties of a variety of medical isotopes. Isotope selection considerations include radiation type, energy emission, and half-life. Many modern radioisotopes ca

Slide 8: Broad opportunity for combination therapies
Accelerating Precision MedicineTM Radiopharmaceuticals offer an extremely broad potential opportunity for combination therapies 8 Monotherapy and expected synergistic MoA with existing therapeutic classes MonotherapyActivation of anti-tumor immunity Sensitization to DNA Damage Response Inhibitors (D

Slide 9: Platform overcomes barriers to radiopharmaceutical commercialization
Accelerating Precision MedicineTM POINT’s platform overcomes the barriers that have prevented radiopharmaceutical commercialization 9 ManufacturingLate-Stage Programs There are currently no large-scale contract radiopharmaceutical manufacturing facilities Only three therapeutic radioligands currentl

Slide 10: Manufacturing and supply chain are key success factors
Accelerating Precision MedicineTM Manufacturing and supply chain are the key success factors: radiopharmaceuticals are made just- in-time with a useable life measured in days 10 POINT’s 100% owned & operated Indianapolis, Indiana manufacturing facility is currently supplying doses for the company’s

Slide 11: Lutetium-177 and actinium-225 supply chains are industry-leading
Accelerating Precision MedicineTM POINT’s Facility 11 POINT’s lutetium-177 and actinium-225 supply chains are industry-leading Internal 177Lu production capability will provide a COGS advantage and supply chain redundancy Redundant 225Ac supply from partners with access to rare Thorium and Radium in

Slide 12: POINT is positioned to be a leader in next-generation radiopharmaceuticals
Accelerating Precision MedicineTM POINT is positioned to be a leader in next-generation radiopharmaceuticals 12 Program Target Clinical Candidate Discovery Preclinical Phase 1 Phase 2 Phase 3 PSMA 177Lu-PSMA I&T PSMA 177Lu-PSMA I&T SSTR 177Lu-DOTA-TATE FAP-α 177Lu-PNT6555 FAP-α 225Ac-PNT6555 PSMA 22

Slide 13: CanSEEK technology designed to improve precision and safety of radioligands
Accelerating Precision MedicineTM POINT is creating the future of radiopharmaceuticals with technologies like CanSEEK™, designed to improve the precision and safety of all radioligands Images are renderings, created for explanatory purposes only. The CanSEEKTM technology has been sub-licensed from b

Slide 14: Anticipated Milestones & Financial Summary
Accelerating Precision MedicineTM Anticipated Milestones & Financial Summary 14 Balance Sheet $252.8M cash & cash equivalents, as of Sept 30, 2021 Projected Runway Cash to fund operations into the first quarter of 2024 Capital Structure 90.1M Common Shares + 3.6M Options Program Clinical Candidate I

Slide 15: Programs: 177Lu-PNT2002 PSMA-Targeted Ligand for mCRPC
Accelerating Precision MedicineTM Programs: 177Lu-PNT2002 PSMA-Targeted Ligand for mCRPC Top Line Data: Mid-2023

Slide 16: PNT2002 is a PSMA-targeted therapy for mCRPC
Accelerating Precision MedicineTM PNT2002 is a PSMA-targeted therapy for metastatic Castration-Resistant Prostate Cancer (mCRPC), in an indication with >36,000 post-ARAT pre-chemo patients annually in the US 1. Beauregard et al. SNMMI Mid-Winter Meeting Feb 2022 2. US Patent 11,129,912 Sep 28 2021 1

Slide 17: PSMA is a clinically-validated therapeutic target
Accelerating Precision MedicineTM Prostate Specific Membrane Antigen (PSMA) is a clinically-validated therapeutic target, ideal for prostate cancer therapy 1. Hupe MC. et al. 2018. Front. Onc. 2. Pangalos MN. et al. 1999. J. Biol. Chem. 3. Davis M. et al. 2005. PNAS 4. Murphy GP. et al. 2000. Prosta

Slide 18: PNT2002's Phase 3 Study for mCRPC: The SPLASH Protocol
Accelerating Precision MedicineTM PNT2002’s Phase 3 Study for mCRPC: The SPLASH Protocol 1. De Bono et al. N Engl J Med 2020; 382:2091-2102 2. Sweeney et al. AACR 2020 18 Study Evaluating Metastatic Castrate Resistant Prostate Cancer Using 177Lu-PNT2002 PSMA Therapy versus Abiraterone or Enzalutamid

Slide 19: Cumulative Administered Activity SPLASH Trial Lead-In
Accelerating Precision MedicineTM 19 Cumulative Administered Activity SPLASH Trial Lead-In1 (N=27) Median Dose 6.8 GBq / 4 cycles Total Kidneys 19.9 Gy Total Red Marrow 0.91 Gy Total Lacrimal Gland 33.7 Gy Total Salivary Gland 9.15 Gy PNT2002 (PSMA-I&T) Baum2 Median Dose 5.8 (3.6-8.7) GBq / 2 (1-5)

Slide 20: Four DSMB meetings completed with no recommended changes
Accelerating Precision MedicineTM 20 Four DSMB meetings completed to date with no recommended changes to study conduct or protocol FDA agreement to proceed with randomization ahead of schedule in December 2021 Red marrow dosimetry well below critical thresholds enabling the potential opportunity for

Slide 21: Randomization has begun in US and Canada
Accelerating Precision MedicineTM Randomization has begun in US and Canada, ongoing EU expansion to expedite accrual 21 Initiate EU Expansion Q4 2021 Start of US Randomization December 2021 Present Dosimetry Data at SNMMI February 2022 NDA Planning and Continued FDA Engagements Q2 2022 – Q3 2023 Top

Slide 22: Programs: 177Lu-PNT2003 SSTR Targeting Ligand for Neuroendocrine Cancer
Accelerating Precision MedicineTM Programs: 177Lu-PNT2003 SSTR Targeting Ligand for Neuroendocrine Cancer

Slide 23: PNT2003 is a somatostatin receptor targeted treatment for NETs
Accelerating Precision MedicineTM PNT2003 is a somatostatin receptor targeted treatment for Neuroendocrine cancer (NETs) 1. Oronsky B. et al. 2017, 2. Dasari A. et al. 2017. 23 NETs are heterogeneous tumors that originate in neuroendocrine cells1. • PNT2003 uses the SSTR-targeted DOTA- TATE ligand,

Slide 24: Somatostatin receptors are a validated target for NETs therapy
Accelerating Precision MedicineTM Somatostatin receptors (SSTRs) are a validated target for NETs therapy 1. Caplin ME. et al. 2014. NEJM 2. Rinke et al. 2009. JCO. 3. Patel YC. et al. 1997. Endocrin. Metabo. 4. Yang SK. et al. 2007. Clin. Exp. Pharm. Phys. 5. Papotti M. et al. 2002. Virch. Arch. 24

Slide 25: PNT2003's reduced radiation safety burden offers differentiation
Accelerating Precision MedicineTM PNT2003’s reduced radiation safety burden offers a significant opportunity for differentiation from the currently approved radiopharmaceutical product for the GEP-NETs indication 25 The 177Lu in PNT2003 does not contain long-lived radioactive impurities, resulting i

Slide 26: NETs is a large market opportunity with multiple regulatory pathways
Accelerating Precision MedicineTM Neuroendocrine Tumors (NETs) is a large market opportunity; there are multiple potential regulatory pathways available to PNT2003 (DOTA-TATE) 1. Oronsky B. et al. 2017. Neoplasia 2. NETs – SEER 18 3. Dasari A. et al. 2017. JAMA 4. Man D. et al. 2018 26 POINT is curr

Slide 27: Next Generation: Novel Targets, Improved Ligands, and Transformational Technologies
Accelerating Precision MedicineTM Next Generation: Novel Targets, Improved Ligands, and Transformational Technologies

Slide 28: The next generation of radiopharmaceuticals
Accelerating Precision MedicineTM The next generation of radiopharmaceuticals will require novel targets, improved ligands, and transformation technologies 28 Novel Targets Improved Ligands Transformational Technologies Pan-cancer approaches Better patient outcomes Enhanced therapeutic windows PNT20

Slide 29: Programs: PNT2004 Fibroblast Activation Protein-α Targeting Ligand
Accelerating Precision MedicineTM Programs: PNT2004 Fibroblast Activation Protein-α Targeting Ligand for Multiple Tumor Types

Slide 30: PNT2004 is a best-in-class FAP-α targeted radioligand
Accelerating Precision MedicineTM PNT2004 is a best-in-class Fibroblast Activation Protein (FAP-α) targeted radioligand with potential for imaging and therapy 30 An ideal radiopharmaceutical targets and is retained in tumors, while flushing out of tissues absent of the target quickly. Developed in c

Slide 31: FAP-α is a pan cancer target found in >90% of epithelial tumors
Accelerating Precision MedicineTM FAP-α is a compelling pan cancer target for imaging and therapy that is found in >90% of epithelial tumors1 1. Mhawech-Fauceglia P. et al. 2015. Canc. Microenv. 2. Jacob M. et al. 2012. Curr. Mol. Med. 3. Mariathasan S, et al. 2018. Nature 4. Domen A. et al. 2021. C

Slide 32: 68Ga-PNT6555 biodistribution shows fast tumor targeting
Accelerating Precision MedicineTM PNT6555 is the lead of the PNT2004 program. 68Ga-PNT6555 biodistribution studies demonstrate fast tumor targeting with little accumulation in normal tissues 32 Rapid renal clearance of excess compound and good tumor retention with low background in other organs. 68G

Slide 33: 177Lu-PNT6555 biodistribution shows prolonged tumor retention
Accelerating Precision MedicineTM 177Lu-PNT6555 biodistribution studies demonstrate prolonged tumor retention and rapid normal tissue clearance 33 Rapid and persistent tumor targeting beyond 7 days with low retention in normal tissues, with exquisite tumor / kidney ratio. Organ uptake 177Lu-PNT6555

Slide 34: 177Lu-PNT6555 shows anti-tumor activity with long-term survival
Accelerating Precision MedicineTM 177Lu-PNT6555 shows compelling anti-tumor activity, with mice experiencing long-term survival 34 Tumor Volumes on Day 22Tumor Volumes Kaplan-Meier Survival Curves HEK-mFAP model, n=6/group, single dose treatment in mice with tumors (~200mm 3), ns=not significant, *p

Slide 35: PNT2004 is on track for a CTA Submission in Q1 2022
Accelerating Precision MedicineTM PNT2004 is on track for a CTA Submission in Q1 2022 35 Lead selected. IND-enabling efficacy, biodistribution and toxicology studies complete. Additional studies in syngeneic and PDX models underway. Process and method optimization and validation with target complete

Slide 36: Programs: PNT2001 Next-Generation PSMA Targeting Ligand
Accelerating Precision MedicineTM Programs: PNT2001 Next-Generation PSMA Targeting Ligand

Slide 37: PNT2001 is a next-generation PSMA radioligand
Accelerating Precision MedicineTM PNT2001 is a next-generation PSMA radioligand optimized for earlier treatment & delivery of 225Ac 37 1. NPCR and SEER 2005-2016 Registries 2. Scher et al. PLOS ONE, 2015 3. Borofsky et al. Radiology, 2017 4. POINT Primary Market Research, Dec 2020 5. Thoma et al. Na

Slide 38: PNT2001 linker technology increases internalization and tumor uptake
Accelerating Precision MedicineTM PNT2001 has linker technology that allows for increased internalization into cells, resulting in increased tumor uptake Unpublished data 38 This profile could result in the same outcomes seen with today’s technology at a lower dose, potentially allowing for a reduct

Slide 39: 225Ac-PNT2001 shows efficacy in pre-clinical tumor models
Accelerating Precision MedicineTM Unpublished data LNCaP model, n=6/group, single dose treatment in mice with large tumors (~600mm 3), ns=not significant, *p<0.05, **p<0.01, ***p<0.001, **** p<0.0001 39 Next step: IND-enabling studies in 2022 225Ac-PNT2001 shows compelling efficacy as a single dose

Slide 40: Programs: CanSEEK FAP-α Activated Prodrug Technology Platform
Accelerating Precision MedicineTM Programs: CanSEEK™ FAP-α Activated Prodrug Technology Platform

Slide 41: Off-target delivery is limiting usage of next-generation radioisotopes
Accelerating Precision MedicineTM Early 225Ac clinical data demonstrates the off-target delivery is limiting usage of next-generation radioisotopes 41 1. Kratochwil, C, et al. J Nucl Med 2016 2. Zacherl, M, et al. J Nucl Med 2020 3. Ruigrok, E, et al. Pharmaceceutics 2019 3 cycles of 9-10 MBq 225Ac-

Slide 42: CanSEEK prodrug platform improves precision, efficacy and safety
Accelerating Precision MedicineTM The goal of the CanSEEK™ prodrug technology platform is to improve precision, efficacy and safety of all radioligands 1. Mhawech-Fauceglia P. et al. 2015. Canc. Microenv. 42 • CanSEEK™, currently in pre-clinical development, prevents a radioligand from binding to re

Slide 43: CanSEEK enables re-evaluation of known ligands
Accelerating Precision MedicineTM CanSEEK™ is as a radiopharmaceutical drug platform that enables re-evaluation of known ligands previously set aside due to off-target delivery concerns 43 • By extending the therapeutic index of ligands, CanSEEK™ could also enable the use of emerging medical isotope

Slide 44: Summary & Milestones
Accelerating Precision MedicineTM Summary & Milestones

Slide 45: POINT will drive innovation in radiopharmaceuticals
Accelerating Precision MedicineTM POINT will drive innovation in radiopharmaceuticals by overcoming their current limitations 45 THE FUTURE OF RADIOPHARMACEUTICALS CanSEEK™ prodrug technology in development to increase efficacy and safety Partnering with sources of emerging alpha, beta and auger emi

Slide 46: Anticipated Milestones & Financial Summary
Accelerating Precision MedicineTM Anticipated Milestones & Financial Summary 46 Program Clinical Candidate Indication Timing (Est.) Milestone Completed Manufacturing 177Lu-PSMA I&T mCRPC Q4 2021 IND Amendment to add facility to supply chain 177Lu-PSMA I&T mCRPC Q1 2022 Dosimetry presentation from 27

Slide 47: Contact
Accelerating Precision MedicineTM 47 NASDAQ: PNT Accelerating Precision Medicine™ investors@pointb iopharma.com POINTBiopharma.com
Source: SEC EDGAR · 8-K filed Feb 25, 2022

